CPVT1 point mutations in RyR2 S5 and S6 segments and their Ca2+ signaling consequence
Cell Calcium · 2025
DOI: 10.1016/j.ceca.2025.103081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Calcium, 2025. Verfasst von Xiao-Hua Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Signaling Center of University of South Carolina, Medical University of South Carolina and Clemson University, USA. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Calcium Signaling, Tachycardia, Ventricular, Point Mutation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, Blue Cross Blue Shield of Massachusetts Foundation.
Abstract (Originalsprache)
Precise activation of cardiac ryanodine receptor (RyR2) by small influx of Ca2+ during the action potential triggers the release of SR Ca2+ that activates contraction, a process known as Ca2+-induced Ca2+ release (CICR). Missense mutations in RyR2 often cause aberrant and unregulated Ca2+ releases that are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), often lethal arrhythmias. Here using CRISPR/Cas9 gene editing in human induced pluripotent stem cells (hiPSCs), we extended our previous studies to include two new arrhythmogenic mutations one, R4822H, located in S5-S6 transmembrane luminal loop near RyR2 selective filter and the other, L4865V, located on S6 segment. TIRF-imaging of voltage-clamped mutant myocytes showed that ICa and caffeine-triggered cytosolic Ca2+ rise (Fura-2 signal) or ER-GCaMP6 SR Ca2+ release signals were significantly suppressed in R4822H but not in L4865V myocytes. Spontaneous Ca2+ transients, however, persisted in both mutant lines activating both Fura-2 and ER-GCaMP6 Ca2+ transients in L4865V cells, but only Fura-2 Ca2+ transients in R4822H mutant. Spontaneous Ca2+ sparks igniting frequencies were similar in both mutants, but spark durations were significantly shorter. Although both of these mutations are located at S5 and S6 transmembrane regions of RyR2, their phenotypes diverge markedly. L4865V mutant does not show suppressed E-C coupling function, while R4822H mutant has completely suppressed CICR suggesting that the spontaneous beating in R4822H mutant results from remodeling of dormant Ca2+ signaling pathway expressed in hiPSCCMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiac Signaling Center of University of South Carolina, Medical University of South Carolina and Clemson University, USA.
- Cardiac Signaling Center of University of South Carolina, Medical University of South Carolina and Clemson University, USA; College of Charleston, Charleston SC, USA.
- Cardiac Signaling Center of University of South Carolina, Medical University of South Carolina and Clemson University, USA; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina.
- Cardiac Signaling Center of University of South Carolina, Medical University of South Carolina and Clemson University, USA; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina. Ele…
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- Blue Cross Blue Shield of Massachusetts Foundation
- National Heart Lung and Blood Institute Division of Intramural Research
Zitieren
APA
Zhang, X. H., Donch, G. E., Yamaguchi, N., & Morad, M. (2025). CPVT1 point mutations in RyR2 S5 and S6 segments and their Ca2+ signaling consequence. Cell Calcium. https://doi.org/10.1016/j.ceca.2025.103081
Vancouver
Zhang XH, Donch GE, Yamaguchi N, Morad M. CPVT1 point mutations in RyR2 S5 and S6 segments and their Ca2+ signaling consequence. Cell Calcium. 2025. doi:10.1016/j.ceca.2025.103081
BibTeX
@article{Zhang2025,
author = {Zhang, Xiao-Hua and Donch, Grace Ellen and Yamaguchi, Naohiro and Morad, Martin},
title = {CPVT1 point mutations in RyR2 S5 and S6 segments and their Ca2+ signaling consequence},
journal = {Cell Calcium},
year = {2025},
doi = {10.1016/j.ceca.2025.103081}
}
EUVIMED